YOLFTbeta
Cleo Diagnostics Ltd

Cleo Diagnostics Ltd

COV · AU · Healthcare / Medical Devices

0.27AUD-0.02 (-6.90%)

Price History

Full chart

Market Stats

Previous Close0.29
Open0.29
Day Range0.27 – 0.29
52-Week Range0.27 – 0.90
Volume154.65K
Market Cap49.12M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
Beta0.36
50-Day Avg0.3328
200-Day Avg0.5134

About

Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Richard Allman Ph.D.
  • Employees0
  • Headquarters480 Collins Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.cleodx.com

Leadership

  • Dr. Richard Allman Ph.D.MD, CEO & Executive Director · b. 1960
  • Dr. Andrew N. StephensChief Scientific Officer & Executive Director
  • Prof. Thomas William JoblingLead Medical Advisor & Independent Non-Executive Director
  • Mr. Nathan HodgsonHead of Operations
  • Ms. Dayna LoucaHead of Corporate Development
  • Ms. Pauline M. Moffatt AAICD, B.Com., FGIACompany Secretary

Financials

Income Statement

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue0110.08K600.15K1.18M-
Growth (%)--+445.19%+97.41%-
Operating Income-23.31K-1.58M-3.61M-3.90M-7.89M
Operating Margin--1431.48%-602.00%-329.07%-
EBITDA--1.57M-3.67M-5.12M-7.82M
EBITDA Margin--1430.69%-612.10%-432.44%-
Net Income-43.93K-1.73M-3.76M-4.00M-5.94M
Net Income Margin--1571.13%-626.38%-337.55%-
Interest Expense-110.78K26.52K--
Interest Expense % of Total Revenue-100.63%4.42%--

Balance Sheet

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets243.61K1.08M9.88M6.94M6.68M
Total Liabilities285.89K2.02M486.22K1.10M1.67M
Total Equity-42.28K-943.42K9.39M5.83M5.01M
Cash42.75K239.77K7.32M747.02K6.22M
Net Debt-1.36M---

Cash Flow

Currency: AUD2023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-684.47K-2.03M-2.90M-
Investing Cash Flow-340.24K-3.05K-11.12K-
Financing Cash Flow1.22M11.17M04.71M
Capital Expenditure340.24K3.05K11.12K9.42K
Free Cash Flow-1.02M-2.03M-2.91M-4.95M
FCF to OCF149.71%100.15%100.38%-

Earnings

Report DateFeb 27, 2025Aug 26, 2025
EPS Estimate0.000.00
EPS Actual-0.02-0.01
Surprise--
Timing--

Key Statistics & Ratios

Market Cap49.12M
Enterprise Value35.78M
Trailing P/E0.00
Forward P/E0.00
Price / Sales28.61
Price / Book8.38
EPS-0.04
Book Value0.037
Revenue (TTM)1.72M
Gross Profit (TTM)1.72M
EBITDA-5.62M
Profit Margin0.00%
Operating Margin-330.81%
Return on Equity-109.48%
Return on Assets-52.15%
Shares Outstanding142.38M
Shares Float80.14M
Beta0.36
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%